Indian Company Master Data Made Simple
Search:
MCA
GSTIN
LEI
Udyam
Directors
36+ lakh companies in our registry
Parmax Pharma Limited
Founded in 1994, Parmax Pharma Limited has been operating for more than 31 years. Parmax Pharma Limited is registered with CIN L24231GJ1994PLC023504 (reg. no. 23504). It falls under the category of company limited by shares. The company has an authorized share capital of ₹6.00 crore. It has a paid-up capital totaling ₹3.74 crore.
Parmax Pharma Limited primarily operates in manufacture of chemicals and chemical products. It is incorporated within the Ahmedabad registry. Its official registered office is situated at Plot No. 20, Survey No. 52, Rajkot-gondal National Highway No. 27, Rajkot, Hadamtala, Gujarat, India, 360311. Currently, the company’s operational status is active. The Permanent Account Number assigned to the company is AADCP9295L. Parmax Pharma Limited is identified globally under LEI 335800838LWBPQU5MJ05. For inquiries or official matters, please email info@parmaxpharma.com. Senior management roles are held by Keyur Dineshbhai Vora (CFO).
Company Overview
- CIN
- Date of Incorporation
- 01/11/1994
- Company Status
- Active
- RoC
- Ahmedabad
- Registration Number
- Balance sheet date
- 31/03/2024
- Company Category
- Company limited by shares
- Company Sub Category
- Non-government company
- Listed in Stock Exchange
- Yes
- Class of Company
- Public Limited Company
- LEI Number
- LEI Status
- Issued
- Authorized Capital
- ₹6,00,00,000.00
- Paid up Capital
- ₹3,74,13,000.00
- Activity
- Manufacture Of Chemicals And Chemical Products
- info@parmaxpharma.com
- PAN
GST Numbers
| State | GST Number | Status |
|---|---|---|
| Gujarat | 24AADCP9295L1ZS | Active |
ISIN Numbers
| ISIN | Security | Interest Rate | Maturity Date | FISN | CFI |
|---|---|---|---|---|---|
| INE240T13019 | PARMAX PHARMA LIMITED WARRANTS 29FB28 | - | 29/02/2028 | PARMAX PHARMA/WT 20280229 | RWSTCA |
| INE240T01014 | PARMAX PHARMA LIMITED EQ | - | 12/10/2026 | PARMAX PHARMA/SH VTG | ESVUFN |
| IN8240T01013 | PARMAX PHARMA LIMITED EQ LISTING/TRADING APPROVAL AWAITED | - | 12/10/2026 | PARMAX PHARMA/SH VTG | ESVUFN |
Balance Sheet
| Metric | 31/03/2026 | 31/03/2025 | 31/03/2024 | 31/03/2023 | 31/03/2022 |
|---|---|---|---|---|---|
| Net PPE | ₹785.99L | ₹797.35L | ₹937.57L | ₹950.05L | ₹0.00L |
| Net Debt | ₹1,086.86L | ₹799.82L | ₹585.59L | ₹518.10L | ₹0.00L |
| Goodwill | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Gross PPE | ₹785.99L | ₹1,768.91L | ₹1,997.08L | ₹1,838.39L | ₹0.00L |
| Inventory | ₹784.93L | ₹331.44L | ₹239.49L | ₹430.61L | ₹0.00L |
| Total Debt | ₹1,151.82L | ₹808.86L | ₹590.65L | ₹537.23L | ₹0.00L |
| Common Stock | ₹445.12L | ₹445.12L | ₹445.12L | ₹445.12L | ₹0.00L |
| Current Debt | ₹0.00L | ₹38.50L | ₹0.00L | ₹89.32L | ₹0.00L |
| Share Issued | ₹37.41L | ₹37.41L | ₹37.41L | ₹37.41L | ₹0.00L |
| Total Assets | ₹2,805.33L | ₹1,875.24L | ₹1,533.06L | ₹1,761.26L | ₹0.00L |
| Capital Stock | ₹445.12L | ₹445.12L | ₹445.12L | ₹445.12L | ₹0.00L |
| Long Term Debt | ₹1,151.82L | ₹770.36L | ₹590.65L | ₹447.91L | ₹0.00L |
| Current Assets | ₹1,667.83L | ₹1,000.28L | ₹577.04L | ₹752.88L | ₹0.00L |
| Working Capital | -₹600.45L | -₹303.46L | -₹344.17L | ₹39.22L | ₹0.00L |
| Invested Capital | ₹537.05L | ₹609.99L | ₹601.18L | ₹1,122.81L | ₹0.00L |
| Other Properties | ₹785.99L | ₹172.91L | ₹216.59L | ₹208.40L | ₹0.00L |
| Common Stock Equity | -₹614.78L | -₹198.87L | ₹10.53L | ₹585.59L | ₹0.00L |
| Net Tangible Assets | -₹614.78L | -₹198.87L | ₹10.53L | ₹585.59L | ₹0.00L |
| Tangible Book Value | -₹614.78L | -₹198.87L | ₹10.53L | ₹585.59L | ₹0.00L |
| Current Liabilities | ₹2,268.28L | ₹1,303.75L | ₹921.21L | ₹713.66L | ₹0.00L |
| Stockholders Equity | -₹614.78L | -₹198.87L | ₹10.53L | ₹585.59L | ₹0.00L |
| Other Equity Interest | -₹1,059.89L | -₹643.98L | -₹434.58L | ₹140.47L | ₹0.00L |
| Total Capitalization | ₹537.05L | ₹571.49L | ₹601.18L | ₹1,033.50L | ₹0.00L |
| Investment Properties | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Ordinary Shares Number | ₹37.41L | ₹37.41L | ₹37.41L | ₹37.41L | ₹0.00L |
| Total Non Current Assets | ₹1,137.50L | ₹874.95L | ₹956.02L | ₹1,008.38L | ₹0.00L |
| Cash And Cash Equivalents | ₹64.97L | ₹9.03L | ₹5.05L | ₹19.13L | ₹0.00L |
| Construction In Progress | ₹0.00L | ₹0.00L | ₹10.41L | ₹0.00L | ₹0.00L |
| Goodwill And Other Intangible Assets | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Total Equity Gross Minority Interest | -₹614.78L | -₹198.87L | ₹10.53L | ₹585.59L | ₹0.00L |
| Total Liabilities Net Minority Interest | ₹3,420.10L | ₹2,074.10L | ₹1,522.52L | ₹1,175.68L | ₹0.00L |
| Current Debt And Capital Lease Obligation | ₹0.00L | ₹38.50L | ₹0.00L | ₹89.32L | ₹0.00L |
| Long Term Debt And Capital Lease Obligation | ₹1,151.82L | ₹770.36L | ₹590.65L | ₹447.91L | ₹0.00L |
| Cash Cash Equivalents And Short Term Investments | ₹64.97L | ₹9.03L | ₹5.05L | ₹19.13L | ₹0.00L |
| Total Non Current Liabilities Net Minority Interest | ₹1,151.82L | ₹770.36L | ₹601.31L | ₹462.02L | ₹0.00L |
Cash Flow
| Metric | 31/03/2026 | 31/03/2025 | 31/03/2024 | 31/03/2023 | 31/03/2022 |
|---|---|---|---|---|---|
| Free Cash Flow | -₹325.53L | -₹135.78L | -₹178.31L | -₹60.33L | ₹0.00L |
| Changes In Cash | ₹55.94L | ₹3.93L | -₹35.58L | -₹64.75L | ₹0.00L |
| End Cash Position | ₹64.97L | ₹9.03L | ₹5.10L | ₹40.68L | ₹0.00L |
| Financing Cash Flow | ₹381.47L | ₹139.71L | ₹142.74L | -₹4.42L | ₹0.00L |
| Investing Cash Flow | -₹89.99L | -₹70.14L | -₹158.69L | -₹93.64L | ₹0.00L |
| Operating Cash Flow | -₹235.54L | -₹65.64L | -₹19.63L | ₹33.31L | ₹0.00L |
| Capital Expenditure | -₹89.99L | -₹70.14L | -₹158.69L | -₹93.64L | ₹0.00L |
| Beginning Cash Position | ₹9.03L | ₹5.10L | ₹40.68L | ₹105.43L | ₹0.00L |
Income Statement
| Metric | 31/03/2026 | 31/03/2025 | 31/03/2024 | 31/03/2023 | 31/03/2022 |
|---|---|---|---|---|---|
| EBIT | -₹460.58L | -₹180.96L | -₹513.31L | ₹42.79L | ₹0.00L |
| EBITDA | -₹359.23L | -₹77.79L | -₹342.14L | ₹230.64L | ₹0.00L |
| Basic EPS | -₹0.00L | -₹0.00L | -₹0.00L | -₹0.00L | ₹0.00L |
| Net Income | -₹415.91L | -₹209.40L | -₹575.05L | -₹10.41L | ₹0.00L |
| Diluted EPS | -₹0.00L | -₹0.00L | -₹0.00L | -₹0.00L | ₹0.00L |
| Gross Profit | ₹222.82L | ₹666.85L | ₹85.73L | ₹659.06L | ₹0.00L |
| Pretax Income | -₹584.57L | -₹239.51L | -₹565.59L | ₹4.61L | ₹0.00L |
| Tax Provision | -₹168.66L | -₹30.11L | ₹9.46L | ₹15.02L | ₹0.00L |
| Total Revenue | ₹1,211.16L | ₹2,820.40L | ₹1,105.30L | ₹1,542.43L | ₹0.00L |
| Cost Of Revenue | ₹988.34L | ₹2,153.55L | ₹1,019.57L | ₹883.38L | ₹0.00L |
| Total Expenses | ₹1,676.42L | ₹2,898.11L | ₹1,570.27L | ₹1,462.13L | ₹0.00L |
| Interest Expense | ₹124.00L | ₹58.55L | ₹52.28L | ₹38.17L | ₹0.00L |
| Operating Income | -₹465.26L | -₹77.72L | -₹464.97L | ₹80.30L | ₹0.00L |
| Tax Rate For Calcs | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Normalized EBITDA | -₹359.23L | ₹29.41L | -₹299.03L | ₹270.26L | ₹0.00L |
| Normalized Income | -₹415.91L | -₹115.68L | -₹544.87L | ₹17.32L | ₹0.00L |
| Operating Expense | ₹688.08L | ₹744.57L | ₹550.70L | ₹578.75L | ₹0.00L |
| Operating Revenue | ₹1,211.16L | ₹2,820.40L | ₹1,105.30L | ₹1,542.43L | ₹0.00L |
| Net Interest Income | -₹124.00L | -₹58.55L | -₹60.34L | -₹38.48L | ₹0.00L |
| Total Unusual Items | ₹0.00L | -₹107.20L | -₹43.11L | -₹39.61L | ₹0.00L |
| Basic Average Shares | ₹37.40L | ₹37.39L | ₹37.41L | ₹37.17L | ₹0.00L |
| Diluted Average Shares | ₹37.40L | ₹37.39L | ₹37.41L | ₹37.17L | ₹0.00L |
| Other Operating Expenses | ₹336.24L | ₹342.56L | ₹17.11L | ₹20.61L | ₹0.00L |
| Reconciled Depreciation | ₹101.35L | ₹103.17L | ₹171.17L | ₹187.86L | ₹0.00L |
| Reconciled Cost Of Revenue | ₹988.34L | ₹2,153.55L | ₹1,019.57L | ₹883.38L | ₹0.00L |
| Tax Effect Of Unusual Items | ₹0.00L | -₹13.48L | -₹12.93L | -₹11.88L | ₹0.00L |
| Interest Expense Non Operating | ₹124.00L | ₹58.55L | ₹52.28L | ₹38.17L | ₹0.00L |
| Net Income Common Stockholders | -₹415.91L | -₹209.40L | -₹575.05L | -₹10.41L | ₹0.00L |
| Net Income Continuous Operations | -₹415.91L | -₹209.40L | -₹575.05L | -₹10.41L | ₹0.00L |
| Diluted NIAvailto Com Stockholders | -₹415.91L | -₹209.40L | -₹575.05L | -₹10.41L | ₹0.00L |
| Net Income Discontinuous Operations | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Otherunder Preferred Stock Dividend | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Total Unusual Items Excluding Goodwill | ₹0.00L | -₹107.20L | -₹43.11L | -₹39.61L | ₹0.00L |
| Net Non Operating Interest Income Expense | -₹124.00L | -₹58.55L | -₹60.34L | -₹38.48L | ₹0.00L |
| Net Income Including Noncontrolling Interests | -₹415.91L | -₹209.40L | -₹575.05L | -₹10.41L | ₹0.00L |
| Net Income From Continuing And Discontinued Operation | -₹415.91L | -₹209.40L | -₹575.05L | -₹10.41L | ₹0.00L |
| Net Income From Continuing Operation Net Minority Interest | -₹415.91L | -₹209.40L | -₹575.05L | -₹10.41L | ₹0.00L |
Company Performance (FY23–FY26)
₹28.2 Cr₹21.2 Cr₹14.1 Cr₹7.1 Cr₹0
FY23FY24FY25FY26
Directors
| Appointment | Director name | DIN | Designation | |
|---|---|---|---|---|
| 02/01/2016 | Umang Alkesh Gosalia | 05153830 | Managing Director | View other directorships |
| 02/01/2016 | Keyur Dineshbhai Vora | *****6633Q | CFO | |
| 17/06/2018 | Ami Shah Rajeshbhai | 08158605 | Director | View other directorships |
| 25/04/2023 | Nikhil Sureshchandra Uchat | 08427983 | Director | View other directorships |
| 02/05/2024 | Bhakti Rameshbhai Aghera | *****7822A | Company Secretary |
Business Network
CompanyDirectorNot on WeeDooBoard seatKey rolePast seatOwnership
Directors 5
- Umang Alkesh GosaliaManaging Director
- Nikhil Sureshchandra UchatDirector
- Ami Shah RajeshbhaiDirector
- Bhakti Rameshbhai AgheraCompany Secretary
- Keyur Dineshbhai VoraCFO
Latest Documents
Category:
| Date | Title | Size |
|---|---|---|
| 01/12/2024 | Form MGT-7-28112024 | - |
| 30/10/2024 | Form AOC-4(XBRL)-30102024_signed | - |
| 26/10/2024 | Form AOC-4(XBRL)-26102024 | - |
Similar Companies
| Company | CIN | Address |
|---|---|---|
| Dabur India Limited | L24230DL1975PLC007908 | 8/3 Asaf Ali Road, New Delhi, Delhi, India, 110002 |
| Gujchem Distillers India Limited | L24230GJ1939PLC002480 | - |
| Ind Swift Limited | L24230CH1986PLC006897 | 781industrial Area Phase Ii, Chandigarh, Chandigarh, India, 160002 |
| Lyka Labs Limited | L24230GJ1976PLC008738 | 4801/b & 4802/a Gidc Indutrail Estate, Ankleshwar, Gujarat, India, 393002 |
| Torrent Pharmaceuticals Ltd | L24230GJ1972PLC002126 | Torrent Houseoff Ashram Road Navarangpura 9, Ahmedabad, Gujarat, India, 000000 |
Address
Plot No. 20, Survey No. 52, Rajkot-gondal National Highway No. 27, Rajkot, Hadamtala, Gujarat, India, 360311
Frequently Asked Questions
What is the incorporation date of Parmax Pharma Limited?
The incorporation date of Parmax Pharma Limited is 01/11/1994.
What is the authorized share capital and paid-up capital of Parmax Pharma Limited?
The authorized share capital of Parmax Pharma Limited is ₹6,00,00,000.00. The paid-up capital is ₹3,74,13,000.00.
Who are the current board members & directors of Parmax Pharma Limited?
The current board member of Parmax Pharma Limited are:
- Umang Alkesh Gosalia
- Ami Shah Rajeshbhai
- Nikhil Sureshchandra Uchat
What is the registered address of Parmax Pharma Limited?
The registered address of Parmax Pharma Limited is Plot No. 20, Survey No. 52, Rajkot-gondal National Highway No. 27, Rajkot, Hadamtala, Gujarat, India, 360311.
What is the Corporate Identification Number of Parmax Pharma Limited?
The Corporate Identification Number of Parmax Pharma Limited is L24231GJ1994PLC023504.